Sarcopenia Treatment Market

Global Sarcopenia Treatment Market Size (2023 to 2028)

The global sarcopenia treatment market is expected to grow at a CAGR of 6% from 2023 to 2028 and the market size is predicted to be worth USD 400 million by 2028.

Sarcopenia is a condition that is related to the progressive Loss of Skeletal Muscles and strength, which can cause physical disability or even death if left untreated. It is generally caused by Aging, as it's seen mostly in aged patients and prolonged physical inactivity with poor nutrition is also associated with Sarcopenia as these two factors play a major role in Sarcopenia. Currently, as of 2023, there exists no cure for Sarcopenia, although the symptoms of Sarcopenia are treated with a combination of dietary supplements and nutrition to increase the quality of life of the Sarcopenia Patients

impact of COVID-19 on the global sarcopenia treatment market:

The COVID-19 pandemic had a significant impact on every large-scale industry worldwide. The sarcopenia treatment market had a significant impact by the COVID-19 pandemic as there was an increased demand for sarcopenia treatment. As COVID-19 patients are more susceptible to sarcopenia and vice versa, this is especially true for aging patients. In patients with COVID-19, there were symptoms of temporary sarcopenia for weeks. The reduced physical activity played a major role in the increased demand for sarcopenia treatment. People became more aware of sarcopenia and realized the importance of nutrition and exercise during the COVID-19 pandemic. Exercising is known to alleviate the severity of symptoms of sarcopenia regular exercise was found to restore mitochondria homeostasis and dampen inflammatory responses via a complex exchange of myokines and osteokines signaling between muscle and bone. Overall, the COVID-19 pandemic had a positive impact on the sarcopenia treatment market due to increased demand for dietary supplements and nutrition.

MARKET DRIVERS:

The growing global aging population and increasing cases of malnutrition in developing countries majorly propel the growth of the global sarcopenia treatment market. Sarcopenia is mostly seen in the elderly and aged people. With an increase in the population of the elderly, the cases of Sarcopenia are rising in prevalence. An increase in cases will have a direct impact on the sarcopenia treatment market. The rapid adoption of sedentary lifestyles among the population is predicted to result in the increasing incidence of sarcopenia and contribute to the growth of the sarcopenia treatment market. The increasing prevalence of malnutrition and protein deficiency among the population of developing countries favours the global market growth. The rising awareness of the treatment options for sarcopenia and increasing awareness of the supplements and importance of proteins and vitamins further support the growth of the global sarcopenia treatment market.

MARKET RESTRAINTS:

The high costs associated with the treatment options for sarcopenia are one of the key factors hampering the market growth. Sarcopenia is not curable, and the treatment needs to be continuous for it to be effective. This increases the recurring costs; protein supplements can be very expensive depending on the quality. The dietary supplements and proteins may not be the cause of Sarcopenia in the patient and the supplements are not proven to be completely effective either, combined with the high recurring costs of these medications are a major restraining factor for the sarcopenia treatment market. The exercises are proven to be more effective for Sarcopenia; regular exercise was found to restore mitochondria homeostasis and dampen inflammatory responses via a complex exchange of myokines and osteokines signaling between muscle and bone. Because of the growing awareness, consumers prefer doing basic exercises instead of taking medications.

REPORT COVERAGE:

The research report on the sarcopenia treatment market has been segmented and sub-segmented into Treatment, Route of administration, distribution channel, and region.

Sarcopenia Treatment Market - By Treatment Type

• Protein Supplements
• Vitamin B12 Supplements
• Vitamin D & Calcium Supplements

The protein supplements segment is expected to dominate the global market during the forecast period. Sarcopenia is associated with progressive loss of skeletal muscles. Proteins are the building blocks of the body. Hence Proteins are a necessary supplement to treat Sarcopenia and increase mobility despite the cost associated with it.

The vitamin B12 segment is anticipated to account for a considerable share of the worldwide market during the forecast period. Vitamin B12 is a necessary medication involved in sarcopenia treatment.

Sarcopenia Treatment Market - By Route of Administration:

• Oral
• Parenteral
• Enteral

The oral segment is expected to hold the leading share of the global market during the forecast period. Oral is the simplest and most convenient mode of administration of drugs and supplements, especially for prolonged usage, which is convenient as a treatment for Sarcopenia as the medications and supplements need to be taken regularly. The benefits that the oral route of administration offers are one of the major factors propelling segmental growth. In cases where patients are suffering from Chronic Illnesses or disability due to extreme levels of Sarcopenia, other routes of administration are used.

Sarcopenia Treatment Market - By Distribution Channel:

• Hospital Pharmacies
• Drug Stores & Retail Pharmacies
• Online Pharmacies

The drug stores & retail pharmacies segment is expected to hold the leading share of the worldwide market in the coming years due to the convenience it provides. Consumers can approach the nearest drug stores and retail Pharmacies and buy the supplements and medications in bulk for a whole month. This is particularly convenient for the elderly as most patients of Sarcopenia are elderly and need to take supplements and medications regularly.

The online pharmacies segment is predicted to account for a prominent share of the worldwide market during the forecast period. Online stores are slightly gaining market share. The elderly and aged people are not very tech savvy to order from Online Pharmacies despite the convenience it provides.

The hospital pharmacies segment is anticipated to hold a considerable share of the global market in the coming years. Hospital pharmacies can be a bit challenging and inconvenient as the requirement for medications and supplements would be constant.

Sarcopenia Treatment Market - By Region

• North America

• Europe

• Asia-Pacific

• Latin America

• Middle East & Africa

The North American region dominated the sarcopenia treatment market in 2022 and the domination is most likely to continue throughout the forecast period. Factors such as the population demographics and a higher number of geriatric and aged populations making them prone to sarcopenia majorly propel the North American market. The sarcopenia patients in the North American region also have expendable resources and with high prices of healthcare, the consumers can also opt for the sarcopenia treatment market for preventive measures.

Europe is growing rapidly and will hold the second-largest share of the global sarcopenia treatment market during the forecast period. The European region is also expected to grow at a healthy CAGR during the forecast period owing to the growing aging population in the European region during the forecast period. Europe also has an excellent healthcare infrastructure and a population with disposable income.

The APAC is predicted to register the highest CAGR in the global sarcopenia treatment market during the forecast period due to rising cases of sarcopenia. The patient population suffering from sarcopenia is growing at an alarming rate in the Asia-Pacific region due to malnutrition. The awareness about sarcopenia in the countries of the Asia-Pacific region has seen a spike in recent times, which favors the APAC market growth.

Latin America and the Middle East & Africa are expected to be at a steady growth rate in the global sarcopenia treatment market during the forecast period.

KEY MARKET PLAYERS:

Abbott Laboratories, Inc., American Way (Amway) Corporation, Bayer AG, GlaxoSmithKline plc., Nestle S.A., Pfizer, Inc., Novartis AG, Sanofi, Inc., Zydus Cadila, Ltd and F-Hoffmann La-Roche are some of the major players in the global sarcopenia treatment market.

RECENT MARKET DEVELOPMENTS:

• In 2023, in a new research paper on Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging-US" by Web of Science) Volume 15, Issue 5, entitled, "AAV1.NT-3 gene therapy prevents age-related sarcopenia”. In this new study by researchers from Nationwide Children's Hospital and Ohio State University, it was found that the AAV1.NT-3 Gene therapy can help prevent age-related Sarcopenia during their tests on wild-aged mice. This research is still in its early stages and holds a lot of promise to present a definitive preventive measure for Age-related Sarcopenia.

• In July 2023, Biophytis, an SA-based clinical-stage biotechnology company, filed for approval from the US Food and Drug Administration (FDA) to launch its SARA-31, which is the first-ever Phase III study in sarcopenia. SARA-31 is expected to evaluate the efficacy and safety of Sarconeos (BIO101) their Lead Drug Candidate in treating sarcopenic patients at risk of mobility disability.